Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
HER2 copy number by fluorescence in situ hybridization (FISH) is typically reported relative to the centromere enumeration probe 17 (CEP17). HER2/CEP17 ratio could be impacted by alterations in the number of chromosome 17 copies. Monosomy of chromosome 17 (m17) is found in ~ 1900 cases of early-stage HER2-positive breast cancer annually in the United States; however, the efficacy of HER2-directed trastuzumab therapy in these patients is not well characterized. Here, we retrospectively identified HER2-amplified, stage I–III breast cancers with m17 and characterized the impact of trastuzumab treatment.
From January 1, 2000 to June 1, 2011, we identified 99 women with HER2-amplified m17 breast cancers, as defined by a CEP17 signal of < 1.5 per nucleus and a HER2/CEP17 ratio of ≥ 2.0.
Most HER2-amplified m17 patients were treated with trastuzumab plus chemotherapy (51%, n = 50), whereas 31% (n = 31) received chemotherapy alone and 18% (n = 18) received no chemotherapy. The 4-year overall survival (OS) was superior with trastuzumab compared to chemotherapy alone or no chemotherapy (100 vs. 93 vs. 81%, respectively; p = 0.005). OS was not influenced by estrogen/progesterone-receptor (ER/PR) status, tumor stage, or degree of FISH positivity. A proportion of patients who would be considered HER2-negative by standard immunohistochemistry staging criteria (0–1+) were HER2 amplified by FISH.
In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population.
KeywordsMonosomy 17 Aneusomy 17 HER2 Trastuzumab CEP17 Polysomy 17 HER2-amplified FISH Chromosome 17
This study was supported in part by a National Institute of Health/National Cancer Institute P30CA008748 Institutional grant awarded to Memorial Sloan Kettering Cancer Center.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R (1996) Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Can Res 56:3886–3890Google Scholar
- 17.NCCN Clinical Practice Guidelines in Oncology (2015) Breast Cancer, Version 3.2015. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 24 July 2015
- 21.Frontline T-DM1 Results Disappointing in Phase III MARIANNE Trial (2014) http://www.onclive.com/web-exclusives/Frontline-T-DM1-Results-Disappointing-in-Phase-III-MARIANNE-Trial. Accessed 27 July 27 2015
- 22.Trial identifier NCT01853748 https://clinicaltrials.gov/ct2/show/NCT01853748 Accessed 27 July 2015